Drugs / SION-2222
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07035990 | Jul 2025 → Jun 2026 overdue | cystic fibrosis | Sionna Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SION-2222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07035990 ↗ |
| Route | Oral | “Route of administration: oral” NCT07035990 ↗ |